Skip to main content


Fig. 7 | Cancer Communications

Fig. 7

From: Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo

Fig. 7

LC-3B-involved autophagy inhibition targets death receptor 4/5 to increase to strengthen TRAIL activity. a The viability of SW480 and HCT-116 cells after 24 h pretreatment with 30 nmol/L siRNA (DR4/5) and 48 h-treatment with azithromycin and TRAIL at the indicated concentrations was assessed with the SRB assay. The expression of correlative proteins was assessed by Western blot after 36 h pretreatment with siRNA and 10 h treatment with azithromycin and TRAIL. b The treatment time and dose of the LC-3B siRNA-related experiment were the same as in a. Both cells were exposed to azithromycin (50 µmol/L), TRAIL (15.625 or 100 nmol/L, respectively) and CQ (20 µmol/L) for 48 h. c, d HCT-116 and SW480 cells were treated with siRNA for 36–40 h and later exposed to azithromycin and/or TRAIL for 10 h. e Cells were treated with CQ (20 and 30 µmol/L) for 10 h. Each experiment was repeated three times. The data represent the mean ± SD of three independent experiments. AZM represents azithromycin

Back to article page